Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564389 · ClinicalTrials.gov registry record · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
A Phase 1 study of Atopic Dermatitis and Healthy Participants, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
- 2
- Study locations
NCT06564389 is a Phase 1 study of Atopic Dermatitis and Healthy Participants that is actively recruiting participants, run by Pfizer. The registered enrollment target is 119 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06564389, a Phase 1 study of Atopic Dermatitis and Healthy Participants, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF-07832837
Study Locations (2)
California
- Anaheim Clinical Trials, LLC - Anaheim
Florida
- Miami Dermatology and Laser Research - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2027-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06564389
The ClinicalTrials.gov registry entry for NCT06564389 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (80% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06564389 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.
Frequently Asked Questions
What is clinical trial NCT06564389 about?
NCT06564389 is a clinical study titled "FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients". The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in pa...
What is the current status of trial NCT06564389?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2024-11-05. Estimated completion is 2027-06-02.
What conditions does trial NCT06564389 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Healthy Participants.
What interventions are being tested in trial NCT06564389?
The interventions under investigation include: Placebo (OTHER), PF-07832837 (DRUG).
Who is sponsoring clinical trial NCT06564389?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564389 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
-
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.